{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:00:47Z","timestamp":1761490847875,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10157-019-01772-z","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T07:02:53Z","timestamp":1564988573000},"page":"1288-1297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists\u2019 questionnaire survey"],"prefix":"10.1007","volume":"23","author":[{"given":"Kakuya","family":"Niihata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-7500","authenticated-orcid":false,"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izaya","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"1772_CR1","first-page":"909","volume":"56","author":"Japanese Society of Nephrology","year":"2014","unstructured":"Japanese Society of Nephrology. JSN and MHLW Clinical Practice Guideline for Nephrotic Syndrome 2014. Nihon Jinzo Gakkai Shi. 2014;56:909\u20131028.","journal-title":"Nihon Jinzo Gakkai Shi."},{"key":"1772_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167\u201373. \n                    https:\/\/doi.org\/10.1038\/ki.2008.24\n                    \n                  .","journal-title":"Kidney Int."},{"key":"1772_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.2014.260","volume":"87","author":"N Yoshikawa","year":"2015","unstructured":"Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87:225\u201332. \n                    https:\/\/doi.org\/10.1038\/ki.2014.260\n                    \n                  .","journal-title":"Kidney Int."},{"key":"1772_CR4","unstructured":"Japanese Society of Nephrology. The number of kidney specialists by prefecture. IN: Renal Specialist. \n                    https:\/\/www.jsn.or.jp\/specialist\/listindex.php\n                    \n                  . Accessed 26 Aug 2018."},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2215\/CJN.12331213","volume":"9","author":"M Shinzawa","year":"2014","unstructured":"Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, et al. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol CJASN. 2014;9:1040\u20138. \n                    https:\/\/doi.org\/10.2215\/CJN.12331213\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol CJASN."},{"key":"1772_CR6","unstructured":"OECD health statistics 2014\u2014frequently requested data\u2014OECD [Internet]. 2018. \n                    https:\/\/www.oecd.org\/els\/health-systems\/oecd-health-statistics-2014-frequently-requested-data.htm\n                    \n                  . Accessed 26 Jan 2018."},{"key":"1772_CR7","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397\u2013404. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw157\n                    \n                  .","journal-title":"J Antimicrob Chemother."},{"key":"1772_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.090843","volume":"37","author":"D Cettomai","year":"2010","unstructured":"Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010;37:792\u20139. \n                    https:\/\/doi.org\/10.3899\/jrheum.090843\n                    \n                  .","journal-title":"J Rheumatol."},{"key":"1772_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10157-013-0793-9","volume":"17","author":"M Shinzawa","year":"2013","unstructured":"Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, et al. Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study. Clin Exp Nephrol. 2013;17:839\u201347. \n                    https:\/\/doi.org\/10.1007\/s10157-013-0793-9\n                    \n                  .","journal-title":"Clin Exp Nephrol."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01772-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T23:35:23Z","timestamp":1596497723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01772-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01772-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethical standards"}},{"value":"Honoraria: Hirokazu Okada (Kyowa Hakko Kirin, Daiichi Sankyo Inc., and Mitsubishi Tanabe Parma), Shoichi Maruyama (Kyowa Hakko Kirin Co., Ltd, Chugai pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.), and Yugo Shibagaki (Astellas Pharma, Teijin Pharma, Chugai Pharmaceuticals, Otsuka Pharmaceutical, Dainihon Sumitomo Pharmaceutical, and Daiichi-Sankyo). Research funding: Shoichi Maruyama (Sanwa Kagaku Kenkyusho Co., Ltd. and Rohto Pharmaceutical Co., Ltd.). Subsidies or Donations: Hirokazu Okada (Takeda Pharm., Chugai Pharm., Torii Pharm., Kyowa-Hakko Kirin, Pfizer, Boehringer Ingelheim, Astellas Pharm., Otsuka Pharm., MSD, Shionogi, Novartis, Sumitomo Dainippon Pharm., Mitsubishi Tanabe Pharm., and Daiichi Sankyo Co.), Yugo Shibagaki (Kyowa-Hakko Kirin, Sanwa Chemicals, Baxter, Takeda Pharmaceutical, Teijin Pharma, Tanabe Mitsubishi Pharma, and Pfizer), and Shoichi Maruyama (Asahi Kasei Pharma Co., Astellas Pharma Inc, Alexion Pharma Co., Otsuka Pharma Co., Kyowa Hakko Kirin Co., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co., Chugai pharmac Co. Ltd., Teijin Pharma Ltd., Torii Pharmaceutical Co, Ltd., Baxter Ltd., Pfizer Japan Inc., Bristol-Myers Squibb., MSD K.K., and Mochida Pharma Co. Ltd.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted, and were approved by the Research Ethics Committee of Iwate Prefectural Central Hospital (approval number 1941) and conform to the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Participant consent was waived, as responses to the questionnaire were retrieved anonymously and no individual information of participants was retrieved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}